Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Jan 16, 2023 3:43pm
107 Views
Post# 35226383

RE:RE:RE:RE:Forcing Bioasis to Answer

RE:RE:RE:RE:Forcing Bioasis to AnswerOh, Cresence is plan A.

I misunderstood. Along with a J&J deal that we know nothing about and a Neuramedy that was another "four bats and a bag of balls" deal, Cresence is/was "Plan A."

You do understand, poof, I'm sure, that if xB3 can make losers like the Cresence and Neuramedy stuff into winners that xB3 can also be used for:
  • Brain tumours
  • MS
  • PD
  • glioblastoma
  • AD
  • Neuroinflammation
  • and a whole bunch of other neurodiseases that could be worth $50 billion per year.

But Neuramedy and Cresence are Plan A.

Ok.

I love how you sprinkle little gems like "catalyze" and "synergy" and "transformational" and "validation" throughout your posts.

Let me use those words in my own sentence.

Do you think that the Ellipses leak signalled that deals that would have been transformational for Bioasis and would have provided validation of the xB3 platform by leveraging the synergy between Bioasis and each of its partners would have helped to calalyze a financial and corporate renaissance for Bioasis?

I threw in "leverage" and "renaissance" because they were needed. Apologies for the vociferous pedantry.

Oh my...

jd

<< Previous
Bullboard Posts
Next >>